Suspenion Tablets

Monotherapy, initial therapy. Adults over 14 years of age, initial: 1,200 mg/day in divided doses t.i.d.-q.i.d. The dose may be increased in 600-mg increments q 2 weeks to 2,400 mg/day based on clinical response and thereafter to 3,600 mg/day, if needed.

Conversion to monotherapy. Adults: Initiate at 1,200 mg/day in divided doses t.i.d.-q.i.d. Reduce the dose of concomitant antiepileptic drugs by 1/3 at initiation of felbamate therapy. At week 2, the felbamate dose should be increased to 2,400 mg/day while reducing the dose of other antiepileptic drugs up to another 1/3 of the original dose. At week 3, increase the felbamate dose to 3,600 mg/day and continue to decrease the dose of other antiepileptic drugs as indicated by response.

Adjunctive therapy. Adults: Add felbamate at a dose of 1,200 mg/day in divided doses t.i.d.-q.i.d. while reducing current antiepileptic drugs by 20%. Further decreases of concomitant antiepilep-tic drugs may be needed to minimize side effects due to drug interactions. The dose of felbamate can be increased by 1,200-mg/day incre ments at weekly intervals to 3,600 mg/day.

Lennox-Gastaut syndrome in children, aged 2—14 years. As an adjunct, add felbamate at a dose of 15 mg/kg/day in divided doses t.i.d.-q.i.d. while decreasing present antiepileptic drugs by 20%. Further decreases in antiepileptic drug dosage may be needed to min-

■ imize side effects due to drug interactions. The dose of felbamate may be increased by 15-mg/kg/day increments at weekly intervals to 45 mg/kg/day.

0 0

Post a comment